YTB53
YTB53 is a MNK1 and MNK2 inhibitor with IC50s of 37 nM and 9 nM, respectively. YTB53 inhibits PDGFRα, TRKB and FLT3 in leukemia cells. YTB53 induces cell cycle arrest, apoptosis, pyroptosis, and mitochondrial dysfunction. YTB53 exhibits antiangiogenic effects. YTB53 can be used for the study of acute myeloid leukemia (AML).
For research use only. We do not sell to patients.
- Formula: C18H13N3O2
- Molecular Weight:303.31
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
MNK1 37 nM (IC50) |
MNK2 9 nM (IC50) |
FLT3 0.47 nM (IC50) |
PDGFRα |
TrkB |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MV4-11 | IC50 |
2 nM
|
Inhibits cell growth of MV4-11 cells for 72 h.
Inhibits cell growth of MV4-11 cells for 72 h.
|
42223949 |
In Vitro
YTB53 (copmound 31) (72 h) inhibits cell growth of MV4-11 cells with an IC50 of 2 nM[1].
YTB53 (1 μM; 2 h) inhibits eIF4E phosphorylation at Ser209 in HEK293T cells[1].
YTB53 (1 μM) exhibits strong inhibitory activity against PDGFRα (98.88%) and TRKB (97.43%). YTB53 inhibits FLT3 with an IC50 of 0.470 nM[1].
YTB53 (0.1-10 μM; 24 h) inhibits eIF4E phosphorylation at Ser209 in MV4-11 cells[1].
YTB53 (0.05-0.2 μM; 24 h) induces cell cycle arrest in MV4-11 cells[1].
YTB53 (0.05-0.2 μM; 48 h) induces cell apoptosis and pyroptosis in MV4-11 cells[1].
YTB53 (0.05-0.2 μM; 24 h) effectively triggeres a substantial increase in ROS generation and a concurrent decrease in mitochondrial membrane potential[1].
YTB53 (0.05-0.2 μM; 0-24 h) exerts a dual antiangiogenic action, suppressing both endothelial morphogenesis and migration in human umbilical vein endothelial cells (HUVECs)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HEK293T cells
-
Concentration:1 μM
-
Incubation Time:2 h
-
Result:Demonstrated the most potent activity, nearly completely abolishing p-eIF4E levels at 1 μM.
-
Cell Line:MV4-11 cells
-
Concentration:0.1 μM, 0.3 μM, 1 μM, 3 μM, 10 μM
-
Incubation Time:24 h
-
Result:Completely inhibited the expression of p-eIF4E even at a low concentration of 0.3 μM, while a concentration of 0.1 μM exhibited partial inhibition.
-
Cell Line:MV4-11 cells
-
Concentration:0.05 μM, 0.1 μM, 0.2 μM
-
Incubation Time:24 h
-
Result:Showed a 24 h treatment induced a concentration-dependent arrest at the G0/G1 phase.
-
Cell Line:MV4-11 cells
-
Concentration:0.05 μM, 0.1 μM, 0.2 μM
-
Incubation Time:24 h
-
Result:Inhibited cyclin E-CDK2 activity.
Pronounced downregulation of cyclin B1 and its kinase partner CDC2 (CDK1) disables the core engine required for G2/M progression.
Increased the phosphorylated p53 (p-p53) protein levels.
Decreased the total p53 protein levels.
-
Cell Line:MV4-11 cells
-
Concentration:0.05 μM, 0.1 μM, 0.2 μM
-
Incubation Time:48 h
-
Result:Led to a dose-dependent increase in the proportion of cells undergoing apoptosis.
Revealed a coordinated downregulation of the antiapoptotic proteins Bcl-2 and Bcl-XL, alongside a reduction in the pro-apoptotic protein Bax-a change.
Decreased the inactive forms of caspase-8, caspase-9, and caspase-3.
The levels of both full-length and cleaved PARP remained largely unchanged.
-
Cell Line:MV4-11 cells
-
Concentration:0.05 μM, 0.1 μM, 0.2 μM
-
Incubation Time:24 h
-
Result:Led to significantly elevated levels of lactate dehydrogenase (LDH) and the pro-inflammatory cytokine IL-18.
-
Cell Line:MV4-11 cells
-
Concentration:0.05 μM, 0.1 μM, 0.2 μM
-
Incubation Time:24 h
-
Result:Showed a significant increase in NLRP3 (NOD-like receptor protein 3) protein levels.
Decreased the level of full-length GSDMD (Gasdermin D).
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c nude mice received a 200 μL subcutaneous injection into the right axillary containing a 1:1 (v/v) mixture of human acute myeloid leukemia MV4-11 cells and Matrigel[1].
-
Dosage:10 mg/kg, 20 mg/kg, 40 mg/kg
-
Administration:s.c.; once a day; 14 days
-
Result:Significantly inhibited tumor growth in a dose-dependent manner.
H&E staining revealed no evidence of inflammatory infiltrates, fibrosis, or architectural disruption in these tissues.
Did not significantly suppress ki-67 expression at low and medium doses (10 and 20 mg/kg) but markedly reduced its levels at the highest dose (40 mg/kg).
Significantly downregulated the expression of p-eIF4E, p53, caspase-9, and Bcl-2.
Elicited a strong inflammatory response at lower doses. However, as the dose increased, the level of inflammation decreased markedly.
Chemical Information
-
Molecular Weight 303.31
-
Formula C18H13N3O2
-
SMILES
O=C(N)C1=CC=C(C=C1)C2=CN=C(O2)C3=CC4=CC=CC=C4N3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)